Guangdong Biolight Meditech Co., Ltd. (SHE:300246)
China · Delayed Price · Currency is CNY 17.32
+0.31 (1.82%)
Apr 30, 2026, 1:25 PM CST
SHE:300246 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,091 | 1,095 | 1,048 | 1,178 | 1,164 | 1,074 |
Other Revenue | - | - | 12.68 | 16.18 | 19.98 | 16.74 |
| 1,091 | 1,095 | 1,060 | 1,194 | 1,184 | 1,091 | |
Revenue Growth (YoY) | 4.74% | 3.29% | -11.18% | 0.87% | 8.49% | -21.85% |
Cost of Revenue | 819.12 | 813.86 | 782.58 | 813.77 | 828.57 | 735.25 |
Gross Profit | 271.53 | 281.53 | 277.9 | 380.23 | 355.13 | 355.76 |
Selling, General & Admin | 239.77 | 239.4 | 262.01 | 254.91 | 263.77 | 201.69 |
Research & Development | 68.56 | 69.68 | 76.92 | 85.85 | 87.54 | 74.34 |
Other Operating Expenses | -11.54 | -10.79 | 0.63 | -3.72 | 3.96 | 3.63 |
Operating Expenses | 296.78 | 298.29 | 343.79 | 342.86 | 361.77 | 283.17 |
Operating Income | -25.26 | -16.76 | -65.89 | 37.37 | -6.64 | 72.6 |
Interest Expense | - | - | -27.38 | -14.88 | -11.52 | -11.98 |
Interest & Investment Income | 6.37 | 8.01 | 23.54 | 22.44 | 16.07 | 7.94 |
Currency Exchange Gain (Loss) | - | - | 5.19 | 1.59 | 1.75 | -1.07 |
Other Non Operating Income (Expenses) | -56.03 | -38.81 | -3.16 | -2.24 | -0.95 | -3.42 |
EBT Excluding Unusual Items | -74.92 | -47.56 | -67.69 | 44.29 | -1.29 | 64.07 |
Impairment of Goodwill | - | - | -11.4 | -90.57 | - | -9.46 |
Gain (Loss) on Sale of Investments | -0.06 | - | - | - | - | -0.45 |
Gain (Loss) on Sale of Assets | 0.32 | -0.62 | -0.02 | -0.31 | 0.51 | 0.92 |
Asset Writedown | -28.61 | -28.12 | -9.42 | -23.98 | -0.01 | -0.08 |
Legal Settlements | - | - | -2.19 | -1.81 | - | - |
Other Unusual Items | - | - | 19.6 | 26.23 | 22.94 | 22.87 |
Pretax Income | -103.28 | -76.3 | -71.12 | -46.16 | 22.14 | 77.88 |
Income Tax Expense | -13.67 | -10.89 | -1.08 | 14.8 | -2.49 | 10.62 |
Earnings From Continuing Operations | -89.6 | -65.41 | -70.04 | -60.96 | 24.62 | 67.26 |
Minority Interest in Earnings | -1.59 | -4.02 | -1.4 | -4.23 | -2.49 | -3.47 |
Net Income | -91.2 | -69.43 | -71.44 | -65.19 | 22.13 | 63.79 |
Net Income to Common | -91.2 | -69.43 | -71.44 | -65.19 | 22.13 | 63.79 |
Net Income Growth | - | - | - | - | -65.31% | -81.57% |
Shares Outstanding (Basic) | 264 | 265 | 263 | 264 | 261 | 219 |
Shares Outstanding (Diluted) | 264 | 265 | 263 | 264 | 261 | 219 |
Shares Change (YoY) | 0.75% | 0.77% | -0.51% | 1.23% | 18.96% | -0.26% |
EPS (Basic) | -0.34 | -0.26 | -0.27 | -0.25 | 0.08 | 0.29 |
EPS (Diluted) | -0.34 | -0.26 | -0.27 | -0.25 | 0.08 | 0.29 |
EPS Growth | - | - | - | - | -70.84% | -81.52% |
Free Cash Flow | -50.72 | -77.02 | -112.45 | -91.29 | -71.08 | -82.8 |
Free Cash Flow Per Share | -0.19 | -0.29 | -0.43 | -0.35 | -0.27 | -0.38 |
Dividend Per Share | - | - | - | - | 0.133 | 0.133 |
Dividend Growth | - | - | - | - | - | -50.02% |
Gross Margin | 24.90% | 25.70% | 26.21% | 31.85% | 30.00% | 32.61% |
Operating Margin | -2.32% | -1.53% | -6.21% | 3.13% | -0.56% | 6.65% |
Profit Margin | -8.36% | -6.34% | -6.74% | -5.46% | 1.87% | 5.85% |
Free Cash Flow Margin | -4.65% | -7.03% | -10.60% | -7.65% | -6.00% | -7.59% |
EBITDA | 45.26 | 51.28 | -7.76 | 87.72 | 37.67 | 108.7 |
EBITDA Margin | 4.15% | 4.68% | -0.73% | 7.35% | 3.18% | 9.96% |
D&A For EBITDA | 70.52 | 68.04 | 58.13 | 50.35 | 44.31 | 36.1 |
EBIT | -25.26 | -16.76 | -65.89 | 37.37 | -6.64 | 72.6 |
EBIT Margin | -2.32% | -1.53% | -6.21% | 3.13% | -0.56% | 6.65% |
Effective Tax Rate | - | - | - | - | - | 13.63% |
Revenue as Reported | - | - | 1,060 | 1,194 | 1,184 | 1,091 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.